OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced in January that it has had two abstracts accepted for presentation at ProBiota 2017 in Berlin from 1-3 February 2017. ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiota focused food and pharma industries. The conference is world renowned as a key meeting place for a community of scientists and business leaders who want to translate science into new products in the growing supplements and ingredients market.
CEO Stephen O’Hara talks through the presentation on LP-LDL®: Cholesterol & hypertension reduction – Next generation pre, pro, and synbiotics that he gave at a conference in Berlin on the 3rd Feb 2017 attended by over 250 scientists from around the world.
The two abstracts relate to the work the OptiBiotix Health plc has undertaken on its cholesterol lowering probiotic. The first abstract will cover the results of the clinical study and will be presented as a poster and oral presentation. The second abstract will be presented as a poster and covers the work on species specific microbiome modulators which the Company has used to enhance the cholesterol reducing effect of their cholesterol reducing strain (LP-LDL®). In the case of this strain, it leads to a threefold increase in the strains ability to lower cholesterol.
